接受雄激素剥夺治疗晚期前列腺癌男性中他汀类药物相关死亡率
基于台湾癌症登记2008—2014年数据的回顾性队列研究,纳入5749例仅接受雄激素剥夺治疗的局部晚期或转移性前列腺癌男性。他汀使用与转移性疾病全因死亡率(HR=0.78)和前列腺癌特异性死亡率(HR=0.76)及局部晚期疾病全因死亡率(HR=0.66)显著降低相关。作者认为仅阿托伐他汀、普伐他汀和瑞舒伐他汀与生存改善相关。
要点
- 他汀使用与转移性前列腺癌全因死亡率降低相关(HR=0.78,95%CI 0.70-0.86)。
- 他汀使用与转移性前列腺癌特异性死亡率降低相关(HR=0.76,95%CI 0.68-0.86)。
- 他汀使用与局部晚期前列腺癌全因死亡率降低相关(HR=0.66,95%CI 0.54-0.81)。
核心结论
- 作者认为仅阿托伐他汀、普伐他汀和瑞舒伐他汀与接受雄激素剥夺治疗的晚期前列腺癌患者生存改善相关。
研究设计与样本
- 回顾性队列研究,使用台湾癌症登记2008—2014年数据,纳入5749例局部晚期和转移性前列腺癌男性,这些患者在癌症诊断后第一年仅接受雄激素剥夺治疗。
- 他汀使用者定义为被处方他汀超过28天者。
- 采用逆概率处理加权Cox模型估计他汀使用对全因死亡率和前列腺癌特异性死亡率的影响,并将他汀状态作为时间依赖变量处理。
主要发现
- 中位随访3.6年(从诊断后1年起算),共2259例患者死亡,其中1495例死于前列腺癌。
- 转移性疾病中,他汀使用与全因死亡率显著降低相关(HR=0.78,95%CI:0.70-0.86)。
- 转移性疾病中,他汀使用与前列腺癌特异性死亡率显著降低相关(HR=0.76,95%CI:0.68-0.86)。
- 局部晚期疾病中,他汀使用与全因死亡率显著降低相关(HR=0.66,95%CI:0.54-0.81)。
- 接受阿托伐他汀、普伐他汀、瑞舒伐他汀或匹伐他汀的患者比接受其他他汀的患者显示出更强的死亡率降低。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Before launching large clinical trials to confirm the effects of statins in improving outcomes among men with prostate cancer (PC), the most appropriate target patient population and the type of statins need to be clearly identified. PATIENTS AND METHODS: A retrospective cohort study was conducted using the Taiwan Cancer Registry of 2008-2014. This study included 5749 men with locally advanced and metastatic PC who received only androgen deprivation therapy (ADT) in the first year after their cancer diagnosis. Statin users were defined as anyone who was prescribed statins for >28 days. An inverse probability of treatment-weighted Cox model was used to estimate the effects of statin use on all-cause mortality and PC-specific mortality (PCSM) while treating the statin status as a time-dependent variable. RESULTS: Overall, 2259 patients died, and 1495 of them died of PC during a median follow-up of 3.6 years from 1 year after their diagnosis. Statin use was associated with significant reductions in all-cause mortality (hazard ratio [HR] = 0.78, 95% confidence interval [CI]: 0.70-0.86) and PCSM (HR = 0.76, 95% CI: 0.68-0.86) for metastatic disease and all-cause mortality (HR = 0.66, 95% CI: 0.54-0.81) for locally advanced disease. Patients who received atorvastatin, pravastatin, rosuvastatin or pitavastatin showed a stronger reduction in mortality than those who received other statins. Benefits of statins were consistently observed in men who received post-diagnostic statins, even in those with high comorbidities or an old age. CONCLUSIONS: Our results suggest that only atorvastatin, pravastatin and rosuvastatin were associated with improved survival in advanced PC patients receiving ADT.
引用
- Wu SY, Fang SC, Shih HJ, et al. Mortality associated with statins in men with advanced prostate cancer treated with androgen deprivation therapy. Eur J Cancer. 2019. PMID: 30827745. doi:10.1016/j.ejca.2018.11.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。